Volume 95 Issue 24 | p. 13 | Concentrates
Issue Date: June 12, 2017

Synthetic Genomics makes anticancer DNA

Department: Business
Keywords: pharmaceuticals, oncology, cancer immunotherapy, synthetic DNA

Synthetic Genomics, the biotech firm founded by J. Craig Venter, has opened what it calls the first current Good Manufacturing Practice (cGMP) facility for making synthetic DNA. The company is working with Advaxis on an investigational cancer immunotherapy called ADXS-NEO that will enter a Phase I clinical trial this year. The patient-customized therapy is based on tumor-specific mutations that can trigger an immune response from the patient’s T cells. Advaxis uses Synthetic Genomics’ automated genomic workstation to produce DNA based on the mutations. It inserts the DNA sequence into bacteria to produce the protein that the mutation expresses. The proteins are then taken up by a patient’s antigen-presenting cells to activate a tumor-specific T-cell response.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment